Inside the market strategies of today’s drugmakers
Inside the market strategies of today’s drugmakers Patent protection is expiring for multibillion-dollar medicines later this decade, forcing drugmakers to find new products and markets. From M&A strategies to emerging therapeutic areas, companies are reshaping their commercial approaches to sustain growth. INCLUDED IN THIS TRENDLINE Drug patents protect pharma profits. Track when they’ll expire. Lilly […]
From AI Models to Agentic Workflows: Building Healthcare AI with Local Compute
Healthcare and life sciences organizations are racing to accelerate discovery, improve diagnostics, and advance digital health and medical device innovation with AI. As teams move from single-model experiments to agentic AI workflows that coordinate models, approved tools, and trusted data, they need practical ways to develop, evaluate, and govern those workflows before broader deployment. But […]
Measuring the Value of Patient Advocacy
Envision Pharma Group’s Adaptive Advocacy Impact Framework helps biopharma teams connect patient insights to organizational decisions and meaningful impact across the product life cycle. Designed for patient advocacy leaders and cross-functional partners, this whitepaper explores how measurement can evolve alongside business priorities and patient community needs. Download the whitepaper to explore: Moving beyond activity metrics: […]
Navigating Ethical Challenges of Complex Phase 1 Studies:
Clinical trial design has evolved substantially in recent years. As sponsors implement more complex and adaptive protocols with features like expansion cohorts, the lines between phases are blurring, creating new ethical challenges. Expansion cohorts typically involve larger trial populations than traditional designs—requiring a careful eye toward participant safety. Adaptive trials are iterative, meaning that as […]
The Analytical-First Playbook for Biosimilar Development
This playbook explores how an analytical-first strategy can help biosimilar developers reduce risk, streamline development and speed market entry. Recent FDA and EMA changes are reshaping the path to market for biosimilars, putting greater emphasis on analytical characterization. For developers pursuing a share of the growing biosimilar opportunity, a strong comparative analytical assessment (CAA) can […]
The rise of antibody-drug conjugates in cancer therapy
The rise of antibody-drug conjugates in cancer therapy Antibody-drug conjugates (ADCs) are a growing class of cancer therapies that use targeted antibodies to deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. After years of development, major pharma companies are investing heavily in ADCs, though the technology faces both successes and setbacks across […]
The Hidden Growth Challenge in Biopharma Isn’t Science, It’s People
Discover how HR technology can help biopharma companies attract talent, streamline operations and scale with confidence. Biopharma companies are built to advance science. However, growth can be slowed by workforce challenges. As organizations scale, they must compete for specialized talent, manage complex compliance requirements and create benefits strategies that attract and retain top professionals. This […]
The Right Bottle Assembly Can Make All the Difference
Explore how custom bottle assemblies support safer fluid transfer, greater efficiency and scalable manufacturing. Every fluid transfer can affect product quality, sterility and manufacturing efficiency. As biopharma companies continue adopting single-use technologies, selecting the right bottle assembly — and the right supplier — has become increasingly critical. This infographic explores how custom bottle and carboy […]
Allergic Rhinitis: Building Patient Engagement and Real-World Evidence
Allergy is a complex market in which people navigate both prescription and over-the-counter treatments, often moving between self-management and professional care. Yet traditional evidence sources rarely capture how treatment decisions are made in daily life, why symptoms persist, or what drives people to switch, combine, or discontinue therapies. This white paper explores how digital engagement […]
The latest developments on the gene therapy frontier
The latest developments on the gene therapy frontier Gene therapy has reached clinical reality with three dozen FDA approvals, but mounting safety concerns have intensified regulatory scrutiny. As developers navigate seven-figure price tags and limited adoption, the field balances breakthrough potential against sobering setbacks. INCLUDED IN THIS TRENDLINE Scribe’s Benjamin Oakes on a rare IPO […]